Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19

Abstract

Identifying risk factors is of utmost importance in patients with cardiovascular risk, even more so in those with extremely high risk, who still present with complications despite receiving treatment as secondary prevention. We hypothesized that patients with very high cardiovascular
risk would have genetic resistance to the antiplatelet agent clopidogrel. We performed a cross-sectional descriptive study that included 58 patients with the CYP2C19 genotype in the coronary care unit of the hospital, who were divided into two groups: resistant and non-resistant to therapy. We confirmed that patients in extremely high cardiovascular risk had more genetic resistance to clopidogrel, which caused secondary prevention failure, so they would benefit from individualizing antiplatelet therapy.